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Abstract
Most of the corticosteroids prescribed in dentistry are for topical applications or short-term 
usage, rarely for its systemic effects or for long-term consumption, as in the treatment 
of some medical conditions. Among the various specialties in dentistry, oral and maxil-
lofacial surgery, oral medicine and endodontics are the more frequent users of corticoste-
roids. Corticosteroids are used in oral and maxillofacial procedures to reduce associated 
post-operative inflammation. The most researched outcome on the use of corticosteroids 
in oral and maxillofacial surgery revolves around their impact to reduce post-operative 
pain, swelling and trismus. Topical corticosteroids, on the other hand, are effective in 
treating various oral mucosal lesions including oral ulcerations and oral presentations of 
auto-immune diseases. Corticosteroids are also used as part of the treatment of temporo-
mandibular joint disorders. Intracanal placement of corticosteroids is used in endodontic 
treatment. This chapter reviews the use of corticosteroids in the three specialties of den-
tistry as mentioned.
Keywords: corticosteroids, dentistry, oral and maxillofacial surgery, oral medicine, 
endodontology
1. Introduction
Corticosteroids is one well-known anti-inflammatory group of drugs that is listed in the Dental’ 
Practitioners’ Formulary. Among the various specialties in dentistry, oral medicine, oral and 
maxillofacial surgery and endodontics are the more frequent users of corticosteroids. Most 
of the corticosteroids prescribed in dentistry are for topical applications or short-term usage, 
rarely for its systemic effects or for long-term consumption, as in the treatment of some medical 
conditions. Five years ago, a chapter entitled “The role of Corticosteroids in today's Oral and 
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Maxillofacial Surgery” [1] has been published in the book “Glucocorticoids—New Recognition 
of Our Familiar Friend”. The objective of this chapter is therefore to complement the previous 
publication as well as providing an update on the use of corticosteroids in dentistry, instead of 
merely oral and maxillofacial surgery.
Although corticosteroids were already used in the field of medicine since 1944, it was not until 
1951 that they were introduced to dentistry. Then, Strean published a paper which represented 
the first scientific approach to the general use of corticosteroids in dentistry [2]. Strean and 
Horton [3] and Spies et al. [4] were the first to use (hydro)cortisone for the treatment of oral 
diseases related to local causes and oral manifestations of inflammatory systemic disease. Back 
then, corticosteroids were prescribed as topical medicament as well as systemic medication, 
depending on the oral manifestations of systemic diseases. Topical corticosteroids have proven 
to be effective in treating various oral mucosal lesions including oral ulcerations and oral pre-
sentations of auto-immune diseases. In oral medicine, injection of corticosteroids is part of the 
treatment of temporomandibular joint degeneration.
Corticosteroids are used in oral and maxillofacial surgical procedures to reduce associated 
post-operative inflammation. The suggestion of their use for managing post-operative sequelae 
of dentoalveolar surgery began as an editorial by Kenny in 1954 [5]. Following this, Ross and 
White performed a clinical trial comparing oral hydrocortisone against placebo in a double-
blind study involving third molar surgeries that confirmed the former’s efficacy [6]. The most 
researched outcome on the use of corticosteroids in oral surgery revolves around their effect 
in reducing post-operative pain, swelling and trismus. Over the last 6 decades, the use of cor-
ticosteroids for third molar surgery had been studied extensively in different formulations, 
dosings, routes and sites of administration [7]. These corticosteroids include dexamethasone 
(per-oral/p.o.), dexamethasone acetate (intramuscular), dexamethasone sodium phosphate 
(intravenous and intramuscular), methylprednisolone (p.o.), methylprednisolone acetate and 
methylprednisolone sodium succinate (both intravenous and intramuscular) [8]. In recent 
years, a twin-mix combination of 2% lignocaine with 1:200,000 adrenaline and 4 mg dexameth-
asone was even given as an inferior alveolar nerve block [9]. A recent review concluded that 
there are benefits that can be derived from the short-term use of corticosteroids in reducing 
these inflammatory sequelae, with no side effects observed when given using the methods 
listed above [7]. However, the use of corticosteroids for periodontal and implant surgeries has 
not been investigated. The other use of corticosteroids in oral surgery is as medication for vari-
ous cranial nerve disorders and application/injections for the treatment of facial scars [10]. It 
is a standard medication for Bell’s palsy [11], with prednisolone coupled with acyclovir being 
the most popular choice. The recommended dose is prednisolone 60–80 mg daily during first 
5 days with dose tapering over next 5 days [12]. It is a drug within a cocktail with NSAIDs given 
to patients suffering from traumatic trigeminal nerve injuries [13]. One study even reported 
their beneficial effect on lingual and inferior alveolar nerve hypersensitivity following third 
molar surgery [14]. More controversial use of corticosteroids is related to their administration 
to patients with maxillofacial space infection. Low et al. recently reported that corticosteroids 
are useful as adjunct treatment for such cases [15]. Their patients experienced significant clini-
cal improvement with reduction of pain, swelling and trismus, and shortening hospital stay to 
an average of 3.5 days, in addition to omission of surgical intervention in 50% of cases.
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Lastly, corticosteroids are used as exposed pulp lining and intracanal medicament in endodon-
tic therapy. This chapter reviews the use of corticosteroids in the three specialties of dentistry 
as mentioned. It shall answer the routinely asked impression: are dental surgeons and dental 
specialists still at a cross road in deciding whether corticosteroids should be routinely used in 
clinical dentistry?
2. Corticosteroids in oral and maxillofacial surgery
Corticosteroids are used mainly by oral and maxillofacial surgeons to reduce the post-oper-
ative sequelae (pain, swelling and trismus) of dentoalveolar surgery, orthognathic surgery, 
facial fractures and reconstructive surgery [16, 17]. Post-operative nausea and vomiting have 
been reported to be less in patients who were given corticosteroids when these surgeries were 
done under general anaesthesia [18]. In addition, corticosteroids have been proven to improve 
interpalpebral width as well as reducing post-operative pain after surgical repair of orbital 
blowout fractures [19, 20]. Local steroid injection of the tongue base had proven to reduce the 
incidence and severity of post-palatoplasty upper airway obstruction in children undergoing 
cleft palate surgery [21]. A questionnaire survey in North America reported that close to half of 
oral and maxillofacial surgeons stated that they use short-term, high-dose perioperative corti-
costeroids to control post-operative oedema [22]. Only 20% of oral and maxillofacial surgeons 
claimed that they never use it for dentoalveolar surgery [23]. In comparison, corticosteroids are 
less preferred for dentoalveolar surgeries by surgeons in at least one European country [16]. 
Their popularity for dentoalveolar surgeries elsewhere has not been established.
The group of corticosteroids of interest is the glucocorticoids (dexamethasone and betametha-
sone, and prednisolone and methylprednisolone), because of their anti-inflammatory activities 
with little or no effect on fluid and electrolyte balance [7]. Their effect has been well studied 
using the third molar surgery model over the past 6 decades (Table 1). In a study that reviewed 
the reported outcome of corticosteroids over the last 10 years (2006–2015), Ngeow and Lim 
[7] reviewed 34 studies that administered corticosteroids via different routes which included 
intravenous, intramuscular (masseter, deltoid or gluteus), submucosal, endoalveolar and oral 
administrations. They found that benefits could be derived from the short-term use of cortico-
steroids with regards to pain, swelling and trismus control following third molar surgery, with 
no side effects observed. However, there were two limitations to their study, namely restriction 
to studies performed only throughout the last decade, and exclusion of studies that compared 
corticosteroids with other drugs, intervention or treatment, except when the corticosteroid was 
administered with an adjuvant therapy related to third molar surgery, namely an antibiotic.
Some 10 years ago, a systematic review and meta-analysis by Markiewicz et al. [24] reported 
that perioperative administration of corticosteroids produced a mild to moderate reduction in 
swelling and improvement of trismus after third molar surgery. More recently, another three 
meta-analyses specifically reported on the effect of dexamethasone in third molar surgery. Two 
reviewed the effect of submucosal injection of dexamethasone [25, 26], while the third reviewed 
the preemptive effect of dexamethasone [27]. The findings of two meta-analyses on submu-
cosal injection are different. Chen et al. reported that submucosal injection of dexamethasone 
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Ross and White (1958) [6] Hydrocortisone 40 mg (multiple doses) Reduced No 
difference
Reduced —
Ware et al. (1963) [51] Dexamethasone 9 mg or 13.5 mg (multiple doses) No 
difference
— No 
difference
—
Lineberg (1965) [29] Dexamethasone 9 mg (multiple doses) Reduced — Reduced —
Nathanson and Seifert (1964) 
[52]
Betamethasone 0.6 mg; multiple tablets (multiple 
doses)
Reduced Reduced Reduced Reduced ecchymosis
Hooley and Francis (1969) [53] Betamethasone 1.2 g (multiple doses) Reduced Reduced Reduced Increased dry socket (4%)
Messer and Keller (1975) [54] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Caci and Gluck (1976) [55] Prednisolone 5 mg (multiple doses) No 
difference
Reduced Reduced Comparison against papase; reduced 
ecchymosis
Huffman (1977) [56] Methylprednisolone sodium succinate 40 mg or 
125 mg (single dose)
Reduced — — —
Edilby et al. (1982) [57] Dexamethasone 4 mg and 8 mg (Two doses) No 
difference
No 
difference
No 
difference
—
Skjelbred and Løkken (1982) 
[58]
Betamethasone 9 mg (single dose) Reduced Reduced Reduced Given preoperative
Skjelbred and Løkken (1982) 
[59]
Betamethasone 9 mg (single dose) Reduced Reduced — Give post-operative
Skjelbred and Løkken (1983) 
[60]
Methylprednisolone succinate 40 mg (single dose) Reduced — — —
Bystedt and Nordenram (1985) 
[61]
Methylprednisolone 12 mg followed by 4 mg 
(multiple doses)
No 
difference
No 
difference
No 
difference
—
ElHaq et al. (1985) [62] Dexamethasone 10 mg (two doses) Reduced — Reduced Comparison against ulatrasound, 
which is equally as effective
Pedersen (1985) [63] Betamethasone 4 mg (single dose) Reduced Reduced Reduced
Corticosteroids
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Sisk and Bonnington (1985) [64] Methylprednisolone 125 mg (single dose) No 
difference
Reduced No 
difference
Comparison against flurbiprofen or 
placebo
Beirne and Hollander (1986) 
[65]
Methylprednisolone 125 mg (single dose) Reduced Reduced No 
difference
—
Olstad and Skjelbred (1986) [66] Methylprednisolone (multiple tapering doses) Reduced Reduced — —
Holland (1987) [67] Methylprednisolone 40 mg (single dose) Reduced Reduced — —
Troullos et al. (1990) [68] Methylprednisolone 125 mg (single dose) Reduced Reduced Reduced Less effective pain control than 
flurbiprofen or ibuprofen
Neupert et al. (1992) [69] Dexamethasone 4 mg (single dose) No 
difference
No 
difference
Reduced —
Baxendale et al. (1993) [70] Dexamethasone 8 mg (single dose) Reduced Reduced No 
difference
—
Hyrkäs et al. (1993) [71] Methylprednisolone 40 mg (single dose) — Reduced No 
difference
Increased efficacy in pain control in 
combination with diclofenac sodium
Milles and Desjardins (1993) 
[72]
Methylprednisolone 16 mg and 20 mg (two doses) Reduced — No 
difference
—
Schmelzeisen and Frölich (1993) 
[73]
Dexamethasone 6 mg (two doses) Reduced Reduced Reduced —
Schultze-Mosgau et al. (1995) 
[74]
Methylprednisolone 32 mg (single dose) Reduced Reduced — Co-administered with ibuprofen
Esen et al. (1999) [75] Methylprednisolone 125 mg (single dose) Reduced Reduced Reduced —
Dionne et al. (2003) [76] Dexamethasone 4 mg (two doses) — Reduced — Synergistic pain relief with ketorolac
Üstün et al. (2003) [77] Methylprednisolone 1.5 mg/kg or 3 mg/kg (single 
dose)
No 
difference
No 
difference
No 
difference
Comparison of two different doses of 
corticosteroids
Bamgbose et al. (2005) [78] Dexamethasone 8 mg and 4 mg (two doses) Reduced Reduced No 
difference
Co-administered with diclofenac 
sodium
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
López-Carriches et al. (2005) 
[79]
Methylprednisolone 40 mg (single dose) — No 
difference
— Comparison with diclofenac
Moore et al. (2005) [80] Dexamethasone 10 mg (single dose) — Reduced Reduced Synergistic effect with rofecoxib
Tiwana et al. (2005) [81] Dexamethasone 8 mg or methylprednisolone 
40 mg (single dose)
No 
difference
No 
difference
No 
difference
Improved sleep and decreased nausea
Buyukkurt et al. (2006) [82] Prednisolone 25 mg (single dose) Reduced Reduced Reduced Synergistic effect with diclofenac
Graziani et al. (2006) [83] Dexamethasone 4 mg or 10 mg (single dose) Reduced Reduced Reduced —
López-Carriches et al. (2006) 
[84]
Methylprednisolone 40 mg (single dose) Reduced — No 
difference
Comparison with diclofenac
Mico Llorens et al. 2006 [85] Methylprednisolone 40 mg (single dose) Reduced No 
difference
Reduced
Ordulu et al. (2006) [86] Methylprednisolone 1.5 mg/kg (single dose) No 
difference
No 
difference
Reduced Comparison with tube drainage
Grossi et al. (2007) [87] Dexamethasone 4 mg or 8 mg (single dose)
Filho et al. (2008) [88] Dexamethasone 4 mg or 8 mg (single dose) Reduced No 
difference
Reduced No difference between two dosages
Zandi et al. (2008) [89] Dexamethasone 8 mg (single dose) followed by 
methylprednisolone 5 mg (multiple doses)
Reduced Reduced Reduced Comparison against rubber drain, 
which reduced pain and trismus
Vegas-Bustamante et al. (2008) 
[90]
Methylprednisolone 40 mg (single dose) Reduced Reduced Reduced
Chopra et al. (2009) [91] Betamethasone 0.5 mg (single dose) Reduced Reduced Reduced Comparison against paracetamol, 
serratiopeptidase, ibuprofen
Gataa and Nemat (2009) [92] Methylprednisolone 10 mg (single dose) Reduced Reduced Reduced Oral route more effective than 
submucosal route in controlling pain 
and trismus
Tiigimae-Saar et al. (2010) [93] Prednisolone 30 mg (single dose) Reduced Reduced Reduced
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Kang et al. (2010) [94] Prednisolone 10 mg or 20 mg (single dose) No difference between the two 
dosages. Dose need to be more than 
20 mg to be effective
Majid and Mahmood (2011) [95] Dexamethsone 4 mg (single dose) Reduced Reduced Reduced No difference between intramuscular 
and submucosal routes
Majid (2011) [96] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced No difference between intramuscular 
and submucosal routes. Improved 
QoL
Deo and Shetty (2011) [97] Dexamethasone 8 mg (single dose) Reduced Reduced Reduced —
Antunes et al. (2011) [98] Dexamethasone 8 mg (single dose) Reduced Reduced Reduced No difference between submucosal 
and intramuscular (masseter) routes
Kaur et al. (2011) [99] Methylprednisolone 40 mg (single dose) Reduced Reduced Reduced —
Mushtaq et al. (2011) [100] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Boonsiriseth et al. (2012) [101] Dexamethasone 8 mg (single dose) Reduced Reduced Reduced No difference between oral and 
intramuscular (deltoid) routes
Klongnoi et al. (2012) [102] Dexamethasone 8 mg (single dose) Reduced Reduced No 
difference
Loganathan and Srinivasan 
(2012) [103]
Methylprednisolone 40 mg (single dose) or 
dexamethasone 4 mg (single dose)
Reduced Reduced Reduced No difference between the two drugs
Murugesan et al. (2012) [104] Dexamethasone 1 mg (multiple doses) Reduced Reduced No 
difference
Comparison with serratiopeptidase
Panwar (2012) [105] Prednisolone 5 mg (single dose) Reduced Reduced Reduced —
Acham et al. (2013) [106] Methylprednisolone 60–80 mg based on body 
weight (single dose)
Reduced Reduced Reduced —
Arakeri et al. (2013) [107] Dexamethasone 8 mg (single dose) Reduced Reduced — Comparison with aprotinin (a serine 
protease inhibitor)
Bauer et al. (2013) [108] Dexamethasone 8 mg (single dose) — Reduced — Synergistic effect with ibuprofen
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Bortoluzzi et al. (2013) [109] Dexamethasone 8 mg (single dose) No 
difference
No 
difference
No 
difference
Dexamethasone was combined with 
amoxicillin or placebo
Channar et al. (2013) [110] Dexamethasone 8 mg (two doses) No 
difference
— No 
difference
—
Chaurand-Lara and Facio-
Umaña (2013) [111]
Methylprednisolone 20 mg (single dose) Reduced Reduced — —
Christensen et al. (2013) [112] Methylprednisolone 16 mg (two doses) Reduced Reduced — Co-administered with bupivacaine or 
lignocaine
Flores et al. (2013) [113] Betamethasone 11.4 mg (single dose) Reduced — Reduced Comparison with oral deflazacort
Majid and Mahmood (2013) 
[114]
Dexamethasone 4 mg (single dose) IM deltoid, IV, 
submucosal, endoalveolar, divided doses of 4× 
1 mg)
Reduced Reduced Reduced Improved quality of life
Mehra et al. (2013) [115] Dexamethasone 8 mg (single dose) Reduced Reduced Reduced Synergistic effect with ibuprofen
Nair et al. (2013) [116] Dexamethasone 4 mg (single dose) Reduced No 
difference
No 
difference
—
Warraich et al. (2013) [117] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Agostinho et al. (2014) [118] Dexamethasone 4 mg or 12 mg (single dose) Reduced Reduced Reduced No difference between two dosages
Bhargava et al. (2014) [9] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Ehsan (2014) [119] Dexamethasone 4 mg (single dose) Reduced — Reduced —
Kaur et al. (2014) [120] Methylprednisolone (single dose) Reduced Reduced Reduced Studied the synergistic effects with 
ibuprofen
Marques et al. (2014) [121] Betamethasone 12 mg (single dose) No 
difference
No 
difference
No 
difference
Noboa et al. (2014) [122] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced Submucosal injection is as effective as 
oral intake
Shaikh et al. (2014) [123] Dexamethasone 8 mg (two doses) Reduced — Reduced —
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Ashraf et al. (2014) [124] Methylprednisolone 125 mg (single dose) Reduced Reduced Reduced No difference between submucosal 
and intramuscular (gluteus) routes
Kocer et al. (2014) [125] Methylprednisolone 20 mg (single dose) Reduced Not studied Reduced No difference in reducing trismus. IM 
masseter better in reducing swelling
Selvaraj et al. (2014) [126] Methylpredniolone 40 mg (single dose) Reduced Reduced Reduced No difference between the masseter 
and gluteus intramuscular routes
Vyas et al. (2014) [127] Methylprednisolone 40 mg (single dose) Reduced Reduced Reduced IM masseter more effective
Alcantara et al. (2014) [128] Dexamethasone 8 mg (single dose) or 
Methylprednisolone 40 mg (single dose)
Reduced Reduced Reduced Dexamethasone better in reducing 
swelling and trismus but no difference 
in reducing pain
Darawade et al. (2014) [129] Dexamethasone 8 mg (single dose) or 
methylprednisolone 40 mg (single dose)
Reduced Reduced Reduced Dexamethasone better in reducing 
swelling and trismus but no difference 
in reducing pain
Chappi et al. (2015) [130] Methylprednisolone 5 m (multiple doses) No 
difference
Reduced No 
difference
Comparison against serratiopeptidase
Chaudhary et al. (2015) [131] Dexamethasone 4 mg or 8 mg (single dose) Reduced Reduced Reduced —
Gopalakrishnan et al. (2015) 
[132]
Dexamethasone 4 mg (single dose) Reduced Reduced Reduced Submucosal more effective than 
intramuscular (deltoid) route
Sabhlok et al. (2015) [133] Dexamethasone 4 mg (multiple dose) or 
dexamethasone 4 mg (single dose)
No 
difference
No 
difference
Reduced Continuous oral medication is more 
effective than single IM
Zerener et al. (2015) [134] Dexamethasone 4 mg (single dose) or 
triamcinolone acetonide 4 mg (single dose)
Reduced Reduced Reduced No difference between the two drugs
Dereci et al. (2016) [135] Dexamethasone 8 mg (single dose) Reduced — — —
Paiva-Oliveira et al. (2016) [136] Dexamethasone 8 mg (single dose) No 
difference
No 
difference
Reduced Comparison with ketorolac 
tromethamine
Quadri et al. (2016) [137] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Saravanan et al. (2016) [138] Dexamethasone 4 mg/2 ml (single dose) Reduced Reduced Reduced SC is more effective than IM
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Authors (year) Corticosteroids studied Summary outcomes
Swelling Pain Trismus Others
Al-Dajani et al. (2017) [139] Dexamethasone 0.1 mg/kg (single dose) Reduced Reduced Reduced
Al-Shamiri et al. (2017) [140] Dexamethasone 8 mg (single dose) Reduced Reduced Reduced
Barbalho et al. (2017) [141] Dexamethasone 8 mg (single dose) Reduced No 
difference
No 
difference
Co-administered with nimesulide 
100 mg
Chugh et al. (2017) [142] Dexamethasone 8 mg (single dose) or 
methylprednisolone 40 mg (single dose)
No 
difference
Reduced Reduced Dexamethasone more efficacious than 
methylprednisolone
Gozali et al. (2017) [143] Dexamethasone 8 mg (single dose) — Reduced — —
Khalida et al. (2017) [144] Dexamethasone 4 mg (single dose) Reduced — Reduced —
Lim and Ngeow (2017) [145] Dexamethasone 4 mg or methylprednisolone 
40 mg (single dose)
Reduced Reduced Reduced —
Lima et al. (2017) [146] Dexamethasone Reduced Reduced Reduced Comparison with diclofenac sodium
Lima et al. (2017) [147] Dexamethasone 8 mg (single dose) Reduced Reduced No 
difference
Comparison with diclofenac sodium
Mojsa et al. (2017) [148] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced Post-operative superior to 
preoperative in pain control
Rocha-Neto et al. (2017) [149] Dexamethasone 8 mg (single dose) No 
difference
Reduced Reduced Preoperative superior to post-
operative in swelling reduction
Selimović et al. (2017) [150] Methylprednisolone 32 mg (single dose) — — Reduced Co-administered with meloxicam
Syed et al. (2017) [151] Dexamethasone 4 mg (single dose) Reduced Reduced Reduced —
Table 1. Summary of outcome of various researches related to the use of corticosteroids in oral and maxillofacial surgery, using impacted third molar surgery model.
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reduced not only early and late oedema but also early trismus [25], while Moraschini et al. 
reported that submucosal dexamethasone was effective in reducing pain and swelling, but not 
trismus [26]. The last meta-analysis looking solely on preemptive dexamethasone against other 
oral anti-inflammatories found that it is more effective than methylprednisolone for reduc-
ing swelling and trismus. However, the authors found insufficient evidence to conclude that 
dexamethasone is better than other nonsteroidal anti-inflammatories or methylprednisolone 
as a preemptive analgesic [27]. In term of mode of administration, it has been suggested that 
systemic administration of corticosteroids is more effective [8].
Table 1 summarises all relevant studies on the use of corticosteroids using the third molar 
surgical model throughout the last 61 years. It shows a change in the trend of corticosteroid 
prescription, with low-dose single dose being favoured in the last two decades instead of the 
multiple or high-doses popular in the 1970s till 1990s. However, not many studies have look 
into the effect of corticosteroids in other oral surgical procedures. One reason for this limitation 
is the lack of opportunity to perform standardisation that is needed with other oral surgery/
dentoalveolar surgical procedures. Mead et al. and Linenburg were among the few researchers 
who were able to conduct tests on patients undergoing different types of oral surgical proce-
dure, including third molar surgery [28, 29]. Mead et al. administered oral triamcinolone post-
operatively to 96 patients who had undergone varied oral surgical procedures and reported 
that it was superior to placebo in reducing oedema, pain and trismus [28].
In contrast, Linenburg studied the effect of dexamethasone on patients undergoing treatment 
of cellulitis and trismus due to an infectious process [29]. He reported a higher percentage of 
patients treated with corticosteroids being cured of cellulitis and trismus after 4 days than con-
ventional treatment of hospitalisation, antibiotics, drainage and heat application. Linenburg 
also conducted a trial on 12 patients undergoing a full-mouth or a maxillary alveoloplasty 
and found that oedema and trismus last longer in patients without dexamethasone. A dou-
ble-blinded comparison was performed on 50 patients undergoing both removal of bilater-
ally impacted third molars and full-mouth or maxillary alveoloplasty, and again he found that 
oedema and trismus last longer in patients without dexamethasone [29].
Not many randomised trials have been undertaken to study the effects of corticosteroids in 
oral and maxillofacial surgery. With regards to pain and swelling, its effect in traumatology has 
been studied once only in two separate RCTs; one on patients with blow out fracture [20] and 
the other on those with mandibular fracture [30]. In the observer-blinded study on the effect of 
dexamethasone 30 mg in blowout fracture surgery, Kormi et al. concluded that dexamethasone 
decreased post-operative pain and recommended it as a preemptive analgesic. In comparison, 
Dongol et al. reported that submucosal administration of dexamethasone after open reduction 
and internal fixation for mandibular fractures was effective in reducing post-operative swelling 
and pain. However, they did not observe any significant difference in mouth opening or dif-
ficulty in mandibular function [30].
Systemic corticosteroids are used to prevent post-surgical facial oedema, enhance patient com-
fort and prevent potential upper airway compromise in orthognathic surgery. Several trials 
even hinted a neuroregenerative effect on inferior alveolar nerve affected by orthognathic sur-
gery [31]. Seo et al. reported that corticosteroids have the potential to accelerate the recovery 
66 Years of Corticosteroids in Dentistry: And We Are Still at a Cross Road?
http://dx.doi.org/10.5772/intechopen.71540
127
of sensory impairment and it is desirable to start treatment later than 1 week post-operatively. 
For the record, the first recommendation for using corticosteroids in orthognathic surgery was 
made by Guernsey and DeChamplain [32] who reviewed complications affecting 22 patients 
who underwent sagittal ramisection. They suggested that post-operative swelling could be 
controlled by a regimen of dexamethasone used perioperatively. They described the diminu-
tion of post-operative oedema empirically but did not explain how they arrived at their rec-
ommended regime of corticosteroids. A study undertaken by Munro et al. [33] 2 years later 
however, failed to support this recommendation. There are, however, several trials that later 
confirmed the reduction of swelling in orthognathic patients [17, 34]. Most of them have been 
meta-analysed and/or underwent systematic review by several authors throughout the last 
7 years [35]. Among others, Schaberg et al. reported that perioperative methylprednisolone 
(1 mg/kg) was effective in patients who underwent either a Le Fort I osteotomy or a transoral 
vertical osteotomy, as compared to control patients who were not given this medication [36]. 
Similarly, Weber and Griffin reported a reduction of swelling when dexamethasone was given 
perioperatively in patients undergoing bilateral sagittal split osteotomy (BSSO) [37]. This find-
ing has been confirmed by other authors [34] who recently reported that the most effective dose 
of dexamethasone for bilateral sagittal split osteotomy was 16 mg given preoperatively.
Widar et al. although reported that betamethasone (single dose or multiple repeated dose up 
to 16 mg) reduces swelling, it does not reduce neurosensory disturbances over time in patients 
undergoing bilateral sagittal split osteotomy [17]. Similar findings have been reported by 
Mensink et al. and Pourdanesh et al. [38, 39]. Similar impact on the neurosensory disturbances 
after zygomatic complex fracture has been reported recently by Haapanen et al. [40]. Because 
of the limited number of studies that listed the benefit of administration of corticosteroids in 
orthognathic surgery, there is still a need for more robust evidence to support their use [41].
Although many studies and systematic reviews found that corticosteroids are beneficial in con-
trolling various post-operative sequelae, there are some who discouraged their use because of 
the fear of several potential adverse side effects [42]. A most recent systemic review and meta-
analysis on the perioperative use of corticosteroids in orthognathic surgery although confirmed 
that they reduced facial oedema, found that adverse effects were inconsistently screened and 
reported [37]. The least severe adverse effect is the development of steroid induced acne in 
some female orthognathic surgery patients [43]. Other more severe complications include adre-
nal suppression [44], acute psychiatric reactions such as psychosis or inappropriate euphoria 
[42], a higher infection rate and decreased healing potential.
There are several recent studies that reported conflicting adverse effects with regards to distur-
bance in surgical wound healing, especially in major oral and maxillofacial surgeries. Thorén 
et al. in a retrospective study reported that the rate of disturbance in surgical wound healing 
for patients who had received perioperative steroids was more than twice (6.0%) the corre-
sponding rate for patients who did not receive steroids (2.8%), although this difference was not 
statistically significant. They reported that intraoral surgical approach was a significant predic-
tor to this adverse effect [45]. Snäll et al. in contrast, did not observe similar problem in opera-
tive treatment of mandibular fractures, although they found that older age was a significant 
predictor of impaired healing [46]. However, in another study on open reduction and fixation 
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of zygomatic complex fractures, Snäll et al. reported increased disturbance in surgical wound 
healing and did not recommend the administration of corticosteroids for such surgery [47].
Other serious complications associated with the administration of corticosteroids are acute 
gastrointestinal reactions (abdominal pain, haematemesis, and/or maelena), hyperglycemia, 
superinfection and septicaemia [48] and avascular necrosis of the femoral head [49]. It has been 
reported that common regimes used in orthognathic surgery involve a total dose of 1830 mg 
of methylprednisolone over a 30-hour period, a dosage similar to some short-term, high-dose 
regimens described in orthopaedic case reports of avascular necrosis of the femoral head 
[49]. Hence, there is a potential risk for this group for patients to develop avascular necrosis. 
Fortunately, Precious et al., found no evidence that this has occurred in the only study that 
reviewed the need of total hip replacement in 1276 orthognathic patients. They concluded that 
the use of systemic corticosteroids for short duration in orthognathic surgery is unlikely related 
to AVN of the femoral head and the attendant need for total hip replacement [50].
3. Corticosteroids in oral medicine
3.1. Recurrent aphthous ulcer
Recurrent apthous ulcers top the list of the commonest oral mucosal lesions encountered by 
any dental practitioners. Generally, this condition is self-limiting and resolves within 2–3 weeks 
with the exception of major recurrent aphthous ulcer [162]. Despite it being self-limiting, the 
pain and the frequency of recurrence can be very devastating to the patients. Corticosteroid is 
one of the available treatment options for recurrent aphthous ulcers.
The use of topical corticosteroids can be advocated when topical anesthetic, antiseptics and 
anti-inflammatory agents are no longer effective in relieving the discomfort caused by these 
ulcers. It was suggested to begin with less potent drug such as triamcinolone and moving 
gradually to more potent corticosteroids like clobetasol [163]. These corticosteroids come in the 
form of mouthwashes, ointments, creams and adhesive pastes.
Triamcinolone acetonide 0.1% is the commonly used concentration although it can actually be 
used at concentration ranging from 0.05 to 0.5%, and is usually applied 3–4 times a day [164]. 
For maximum effect of the drug, it should be in contact with the ulcer for as long as possible. 
Therefore, it is advisable to refrain from any oral intake within 20 minutes after application or 
touching the affected area [164]. Fluocinolone acetonide and clobetasol require lower concen-
trations of 0.025–0.05% since they are potent corticosteroid. These drugs are usually applied 
4–5 times a day [164]. Al-Na’amah et al. in 2009 studied the use of dexamethasone 0.1% by 
comparing it to triamcinolone acetonide 0.1% and found that both drugs are effective in the 
treatment of recurrent aphthous ulcers [159].
On the other hand, systemic corticosteroids are rarely required in the treatment of recurrent 
aphthous ulcers except for cases that are not responsive to topical medications [165]. Oral pred-
nisone with starting dose of 25 mg/day is recommended [165]. This is then followed by tapering 
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of the dosage during a period of 2 months. The tapering regime as reported by Femiano et al. 
in 2003 and 2010 (Table 2) had been shown to be effective in the treatment and prevention of 
recurrence of aphthous ulcer [161].
3.2. Oral lichen planus
Table 3 shows that topical corticosteroids are reasonably effective in the treatment of oral 
lichen planus. The use of more potent corticosteroids was associated with more improve-
ment following therapy. However, incidence of oral candidiasis also increased in proportion 
Authors (year) Corticosteroids Outcomes
Pain reduction Ulcer size 
reduction
Duration of 
ulcer
Recurrence
Topical
Yeoman (1978) 
[152]
Betamethasone valerate 1 puff 
QID (max 16 puff/24 hours)
Reduced – Reduced –
Pimlott (1983) 
[153]
0.05% fluocinonide ointment 
+ orabase
Reduced – Reduced Less
Lo Muzio et al. 
(2001) [154]
0.05% clobetasol ointment Reduced – – –
Rhodus and 
Bereuter (1998) 
[155]
Kenalog-in-Orabase, TDS Reduced – Reduced –
Teixeira et al. 
(1999) [156]
0.1% mometasone furoate 
lotion QID
Reduced – Reduced –
Rodriguez (2007) 
[157]
0.05% clobetasol propionate 
oral paste QID × 5 days
Reduced Faster – –
Al-Na’amah et al. 
(2009) [158]
Dexamucobase; 0.1% 
dexamethasone QID
Reduced Faster Reduced –
Al-Na’amah et al. 
(2009) [158]
Kenalog; 0.1% triamcinolone 
acetonide QID
Reduced Fast Reduced –
Fani et al. (2012) 
[159]
0.1% triamcinolone acetonide 
ointment TDS
Significantly better therapeutic effect in triamcinolone group
Systemic
Femiano et al. 
(2003) [160]
Prednisone
25 mg OD × 1 week, 20 mg 
OD × 2 weeks, 15 mg OD × 
2 weeks, 10 mg OD × 2 weeks, 
5 mg OD × 1 week
Reduced – Reduced Less
Femiano et al. 
(2010) [161]
Prednisone
25 mg OD × 15 days, 12.5 mg 
OD × 15 days, 6.25 mg OD 
× 15 days, 6.25 mg EOD × 
15 days
Reduced. – Reduced Less
Table 2. Topical and systemic corticosteroids used in the treatment of recurrent aphthous ulcer.
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to the potency of corticosteroids used [169, 171]. Carbone et al. in 2003 reported that the use 
of topical corticosteroid can be as effective or even more effective than systemic corticoste-
roids in the treatment of oral lichen planus [175]. On the other hand, the use of systemic cor-
ticosteroids should be restricted to acute exacerbations or multiple lesions. Topical regime 
can be prescribed in combination of systemic regime to reduce side effects of systemic cor-
ticosteroids [176]. The commonly used systemic corticosteroid is prednisone which is usu-
ally prescribed within the range of 40–80 mg/day to achieve clinical response. To avoid 
adverse effects of this drug, it is best to prescribe the lowest dose for the shortest duration 
possible. To achieve this, prednisone can either be given for a brief period of 5–7 days and 
stop abruptly or the dose can be tapered down by 5–10 mg/day gradually over a period of 
2–4 weeks [177].
Intralesional injection is another alternative for administrating corticosteroids in the treatment 
of oral lichen planus. Hydrocortisone, dexamethasone, betamethasone, triamcinolone aceton-
ide and methylprednisolone have been used for intralesion injection. This method is however, 
painful and causes localised mucosal atrophy. Intralesional injection is also not feasible in cases 
of multiple widespread lesions [176, 178].
Corticosteroid Author (year) Results (%)
Complete 
response
Partial response No response
Hydrocortisone hemisuccinate Holbrook et al. (1988) [165] 48 37 15
Betamethasone sodium 
phosphate
Hegarty et al. (2002) [166] 0 73 27
Betamethasone valerate 0.1 mg Cawson (1968) [167] 43 23 34
Triamcinolone acetonide 0.1% Thongprasom et al. (1992) 
[168]
42 Not mentioned Not mentioned
Fluocinolone acetonide 0.1% Thongprasom et al. (1992) 
[168]
68 Not mentioned Not mentioned
Fluocinonide 0.05% Lozada and Silverman 
(1980) [169]
52 48 0
Voute et al. (1993) [170] 20 60 20
Carbone et al. (1999) [171] 25 65 10
Fluticasone propionate 0.05% Hegarty et al. (2002) [166] 0 80 20
Clobetasol propionate 0.05% Lozada-Nur et al. (1991) 
[172]
56 22 22
Sardella et al. (1988) [173] 57 21.5 21.5
Carbone et al. (1999) [170] 75 25 0
Gonzales-Moles et al. (2002) 
[174]
93 0 7
Table 3. Topical corticosteroids used in the treatment of oral lichen planus.
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3.3. Pemphigus vulgaris and mucous membrane pemphigoid
Corticosteroids have become the mainstay of treatment for pemphigus ever since the first case 
series reported by Ryan in 1971 [179]. Despite being the gold standard in the treatment of pem-
phigus, the use of corticosteroids is still mulled by many physicians due to the adverse effects of 
long-term treatment and difficulty in ascertaining the best regimen [180]. Due to the high mortal-
ity rate of this condition, studies conducted were just comparing various groups of drugs used, 
different dosages and modes of administration rather than purely investigating the efficacy of 
a particular drug. Most of the articles published were mainly case reports and case series [181].
More than three-quarter of the patients with pemphigus vulgaris presented with oral lesions. 
And these lesions are the presenting signs of half of the patients diagnosed with pemphigus 
vulgaris [182]. As in the treatment of oral lesions in pemphigus vulgaris, oral lesions secondary 
to mucous membrane pemphigoid are also treated with moderate to high potency topical cor-
ticosteroids (fluocinonide 0.05%, clobetasol 0.05%), applied 2–3 times per day. The frequency of 
application can be tapered gradually with improvement of symptoms [182]. Bear in mind that 
as a result of prolonged topical corticosteroids use, infection such as candidiasis and reactiva-
tion herpes simplex virus can occur. Combination of other drugs such as dapsone, tetracycline 
and nicotinamide is recommended.
As for systemic corticosteroids, an initial dose of 0.5–1 mg/kg/day of prednisone plus 
adjuvant immunosuppressants is recommended. This dose is continued until all existing 
lesions have healed and no development of new lesions is noticed clinically. Once this is 
achieved, tapering of the dose can be performed [182]. The ultimate aim in the treatment 
strategy is to minimise the dose of systemic corticosteroids while controlling the disease 
with immunosuppressants.
In patient with severe pemphigus vulgaris, corticosteroid pulse therapy can be administered 
to induce remission. In this therapy, a very high-dose of corticosteroid (500–1000 mg methyl-
prednisolone or 100–200 mg dexamethasone given in divided dose on 3 consecutive days) is 
given in a short period of time in combination immunosuppressants and maintenance dose 
of corticosteroids [183].
3.4. Bell’s palsy
With an unclear knowledge of the aetiology of Bell’s palsy, it poses a great challenge in coming 
up with an optimal treatment of the condition. To achieve a good outcome, corticosteroid needs 
to be given within 72 hours of onset of facial palsy. Berg et al. in 2012 found that prednisolone 
given within 72 hours of onset of palsy significantly improve outcome in mild to moderate palsy 
but not in severe palsy. The regime used was prednisolone 60 mg/day for 5 days, followed by 
10 mg/day for another 5 days [184]. Using the same regimen, another study found that pred-
nisolone significantly achieve complete recovery in mild to severe palsy and less synkinesis 
observed in mild and moderate palsy. However, no significant reduction of synkinesis in severe 
cases was reported [185]. Murthy and Saxena in 2011 suggested two corticosteroid regimens for 
the treatment of Bell’s palsy which were either prednisolone 60 mg/day for 5 days followed by 
10 mg/day for another 5 days or prednisolone 25 mg twice a day for 10 days [186]. The American 
Academy of Otolaryngology-Head and Neck Surgery recommended a 10-day course of oral 
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steroids with at least 5 days at a high-dose (either prednisolone 50 mg for 10 days or prednisone 
60 mg for 5 days with a 5-day taper) initiated within 72 hours of symptom onset [187].
Conflicting results were reported in different studies on the benefit of combining anti viral 
therapy with corticosteroid to achieve better outcome. Minnerop et al. reported that combina-
tion of famciclovir and prednisone was superior to prednisone alone in cases of severe Bell’s 
palsy [188]. Combining antiviral therapy with prednisone increase the recovery rate slightly 
but not significantly compared to prednisone monotherapy [189]. On the other hand, vala-
cyclovir was found to have no additional effect to prednisolone in sequelae of Bell’s palsy 
[869] and the addition of acyclovir to prednisolone did not significantly improve recovery 
from Bell’s palsy [190]. Despite conflicting results from various studies, Madhok et al. in their 
Cochrane review in 2016 concurred with current evidences that corticosteroids showed sig-
nificant benefit in the treatment of Bell’s palsy [191].
3.5. Temporomandibular joint
In year 1953, Horten reported the use of intraarticular injection of steroids into the temporo-
mandibular joint (TMJ) space. Being the first to perform this procedure in the TMJ, he was 
then inspired by Hollander and colleagues’ work where they injected hydrocortisone into other 
arthritic joints [192]. Kopp et al. in 1985 injected betamethasone into the TMJ space in a group of 
patients with TMJ pain and dysfunction, showed that betamethasone was effective in reducing 
joint pain up to 4 weeks [193]. About 6 years later, Kopp and colleagues performed intraarticu-
lar injection using methylprednisolone which showed similar promising results up to 4 weeks 
[194]. Bjørnland et al. injected betamethasone into the TMJ space of patients with osteoarthri-
tis and myofascial pain 10 years ago. Although betamethasone managed to reduce joint pain, 
sodium hyaluronate which was given in the other study group was found to be more effective 
[195]. Another promising use of corticosteroids is for the management of disc displacement 
without reduction. Samiee et al. found that combined intraarticular injection of local anaes-
thetic and corticosteroids improved mouth opening [196].
Using computed tomography (CT) scan, Møystad et al. evaluated the bony changes in osteo-
arthritic TMJ following intraarticular injection of sodium hyaluronate and corticosteroid (beta-
methasone). The number of cases that showed disease progression, regression and no changes 
were almost equal [197]. This finding raised the question on the effectiveness of corticosteroids 
as intraarticular injection. Another study by Bouloux et al. recently again showed no added 
effect of using corticosteroids or another agent, hyaluronic acid in arthrocentesis [198]. In cases 
of juvenile idiopathic arthritis, a study by Resnick et al. showed that although intraarticular 
corticosteroid (triamcinolone hexacetonide) injection did reduce TMJ sinovitis pain, its efficacy 
for long-term inflammation and joint destruction control needs further studies.
4. Corticosteroids in endodontology
The first intracanal medication using corticosteroids was reported by Wolfsohn in 1954. 
In that study, he showed that hydrocortisone was effective in reducing severe secondary 
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inflammatory reactions in the apical periodontal tissue following endodontic treatment 
[208]. Other authors who also used corticosteroids as intracanal medication, as listed in 
Table 4, reported beneficial outcome in the post-operative or post-instrumentation pain. 
Besides reducing pain, Thong et al. reported that the use of corticosteroid-antibiotic and 
calcium hydroxide significantly inhibited periodontal ligament inflammation and inflamma-
tory root resorption [209]. A well-known intracanal medication, Ledermix®, is corticosteroid-
antibiotic compound which consists of 1% triamcinolone acetonide and 3.2% demeclocycline 
hydrochloride in a polyethylene glycol base. The function of antibiotic in that paste is to 
compensate for the possible corticosteroid-induced immunosuppessing effect [210]. Despite 
being an effective intracanal medication, Ledermix® was found to cause discolouration of the 
teeth especially when it is placed above the cementoenamel junction. Therefore, to avoid this 
Ledermix® should be placed below the gingival margin [211].
Similar to the use of corticosteroids in third molar surgery, local injection of corticosteroids 
have been found to reduce post treatment pain. Kaufman et al. evaluated the effect of intra-
ligamental injection of corticosteroids on post treatment pain. They found that intraligamental 
injection of methylprednisolone significantly decreased post treatment pain [202]. Nobuhara 
et al. in their histological study found that local infiltration of dexamethasone significantly 
reduced inflammation of the periapical tissue [212].
Author (year) Corticosteroids Outcome
Post treatment 
pain
Intracanal
Rogers et al. (1999) [199] Dexamethasone 0.4 mg (intracanal) and ketorolac tromethamine 
3 mg (intracanal)
Reduced
Negm (2001) [200] Kenacomb (antibiotics and triamcinolone acetonide 0.1%) Reduced
Ehrmann et al. (2003) [201] Ledermix (1% triamcinolone acetonide, 3.2% demeclocycline) Reduced
Local (injection)
Kaufman et al. (1994) [202] 4–8 mg methylprednisolone (intraligamental injection) Reduced
Systemic
Stewart and Chilton (1958) 
[203]
Metreton (2.5 mg prednisone, 2 mg chlopheniramine) TDS × 2 days, 
penicillin 250 mg TDS × 3 days
Reduced
Stewart (1962) [204] Dexamethasone 0.75 mg BD × 2 days Reduced
Krasner and Jackson (1986) 
[205]
Dexamethasone 0.75 mg × 7 tablets, 3 tablets immediately after 
procedure, one tablet every 3 hours
Reduced
Glassman et al. (1989) [206] Dexamethsone 4 mg × 3 tablets, one tablet taken immediately after 
procedure, one tablet every 4 hours
Reduced
Liesinger et al. (1993) [207] Dexamethasone 0.07–0.09 mg/kg (intramuscular injection) Reduced
Table 4. Studies on usage of corticosteroids via various routes of administration.
Corticosteroids
From the studies shown in Table 4, it is obvious that they confirmed the favourable result of 
systemic administration of corticosteroids in alleviating post treatment pain. In all the studies, 
corticosteroids were only given for a very short period. Therefore, the possibility of adverse 
effects arising from short-term corticosteroids is very unlikely [7].
5. Conclusion
The uses of corticosteroids are very well established in the field of oral medicine and 
endodontology. On the other hand, in the field of oral and maxillofacial surgery, despite 
being consistently effective in controlling post-surgical oedema, corticosteroids provide 
rather less consistent outcome in pain control as well as trismus reduction. Its impact on 
wound healing is varied.
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